Thousand Oaks, CALIFORNIA2 Active Studies

Hidradenitis Suppurativa Clinical Trials in Thousand Oaks, CALIFORNIA

Find 2 actively recruiting hidradenitis suppurativa clinical trials in Thousand Oaks, CALIFORNIA. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
1,835
Enrolling

Recruiting Hidradenitis Suppurativa Studies in Thousand Oaks

About Hidradenitis Suppurativa Clinical Trials in Thousand Oaks

Hidradenitis suppurativa is a chronic skin condition causing painful lumps under the skin, typically in areas where skin rubs together. It can lead to tunnels under the skin and scarring. Treatment includes antibiotics, biologics, and surgical interventions.

There are currently 2 hidradenitis suppurativa clinical trials recruiting participants in Thousand Oaks, CALIFORNIA. These studies are seeking a combined 1,835 participants. Research is being sponsored by AbbVie, Novartis Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.

Hidradenitis Suppurativa Clinical Trials in Thousand Oaks — FAQ

Are there hidradenitis suppurativa clinical trials in Thousand Oaks?

Yes, there are 2 hidradenitis suppurativa clinical trials currently recruiting in Thousand Oaks, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Thousand Oaks?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Thousand Oaks research site will contact you about next steps.

Are clinical trials in Thousand Oaks free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Thousand Oaks studies also compensate for your time and travel.

What hidradenitis suppurativa treatments are being tested?

The 2 active trials in Thousand Oaks are testing new therapies including novel drugs, biologics, and treatment approaches for hidradenitis suppurativa.

Data updated March 2, 2026 from ClinicalTrials.gov